NK cell activity and methylated HOXA9 circulating tumor DNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Sara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, Torben Schjoedt Hansen, Christa Haugaard, Ole Hilberg, Anders Jakobsen, Torben Schjoedt Hansen

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Abstract

Background: PD-1/PD-L1 inhibitors have improved survival for patients with non-small cell lung cancer (NSCLC), but better prognostic biomarkers are needed. Methods: We prospectively collected plasma from 82 patients with NSCLC before initiating treatment with PD-1/PD-L1 inhibitors and before treatment cycles 2-4. We used the NK Vue assay to measure interferon gamma (IFNγ) as a surrogate for natural killer cell activity (NKA) with a cutoff of 250 pg/mL. Circulating tumor DNA (ctDNA) in the form of methylated HOXA9 was measured by droplet digital PCR. ctDNA status was classified as detectable or undetectable ctDNA. Results: Patients were classified into three groups according to IFNγ levels at the available time points. The NKA-low group had a persistently low level of IFNγ or dropped to and remained at a low level after baseline (
OriginalsprogEngelsk
Artikelnummer2552
TidsskriftJournal of Clinical Oncology
Vol/bind40
Udgave nummer16. suppl.
Sider (fra-til)2552
Antal sider1
ISSN0732-183X
DOI
StatusUdgivet - 2022
Begivenhed2022 ASCO annual meeting - McCormick Place, Chicago, USA
Varighed: 3. jun. 20227. jun. 2022

Konference

Konference2022 ASCO annual meeting
LokationMcCormick Place
Land/OmrådeUSA
ByChicago
Periode03/06/202207/06/2022

Citationsformater